E Fund CSI Biotechnology Thematic ETF(159837) rises 6.70%, with a scale increase of 24.4004 million yuan over the past week

NewTimeSpace (newtimespace.com) News, as of 14:27 on June 29, 2026, E Fund Biotechnology ETF (159837) rose 6.70%, with the latest price at 0.46 yuan. Over a longer time frame, as of June 26, 2026, the ETF accumulated a gain of 1.41% over the past week, ranking 2/4 among comparable funds.

In terms of liquidity, E Fund Biotechnology ETF recorded an intraday turnover rate of 5.73% and a trading volume of 83.0946 million yuan. Over a longer time frame, as of June 26, the ETF's average daily trading volume over the past week reached 46.3887 million yuan, ranking first among comparable funds.

In terms of scale, E Fund Biotechnology ETF saw a significant increase of 24.4004 million yuan in scale over the past week, with the new scale increase ranking 1/4 among comparable funds. (Data source: Wind)

In terms of shares, the latest share count of E Fund Biotechnology ETF reached 3.218 billion units, hitting a one-year high and ranking 1/4 among comparable funds. (Data source: Wind)

In terms of capital flows, the latest net inflow for E Fund Biotechnology ETF was 2.1930 million yuan. Over a longer time frame, within the past five trading days, there were four days of net inflow, attracting a total of 20.0227 million yuan, with an average daily net inflow of 4.0045 million yuan. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. The latest margin financing purchase amount of E Fund Biotechnology ETF reached 3.4311 million yuan, with the latest margin financing balance standing at 45.0024 million yuan. (Data source: Wind)

As of June 26, the net value of E Fund Biotechnology ETF rose by 3.42% over the past two years, ranking first among comparable funds. From the perspective of return capability, as of June 26, 2026, since its inception, the ETF achieved a highest single-month return of 24.33%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 30.21%, and an average return of 5.55% in up months. As of June 26, 2026, the ETF's annualized excess return over its benchmark for the past three months was 4.27%, ranking in the top 2/4 among comparable funds.

In terms of drawdown, as of June 26, 2026, E Fund Biotechnology ETF recorded a drawdown of 0.18% relative to its benchmark since the beginning of the year, reflecting lower drawdown risk among comparable funds.

In terms of fees, E Fund Biotechnology ETF has a management fee rate of 0.15% and a custodian fee rate of 0.05%, the lowest fee rates among comparable funds.

In terms of tracking accuracy, as of June 26, 2026, the five-year tracking error of E Fund Biotechnology ETF was 0.033%, achieving the highest tracking accuracy among comparable funds.

It is worth noting that the valuation of the CSI Biotechnology Theme Index, which the fund tracks, is at a historical low. The latest price-to-book (PB) ratio is 3.40x, which is lower than over 90.15% of the time in the past year, highlighting attractive valuation.

E Fund Biotechnology ETF closely tracks the CSI Biotechnology Theme Index. The CSI Biotechnology Theme Index selects the securities of listed companies whose businesses involve genetic diagnosis, biopharmaceuticals, blood products, and other human biotechnology fields as index constituents, in order to reflect the overall performance of biotechnology-related listed company securities.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.